Zenas BioPharma, Inc. Common Stock

Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune and chronic inflammatory diseases. The company's portfolio is anchored by two late-stage franchise molecules: obexelimab, a bifunctional monoclonal antibody that binds CD19 and FcγRIIb to inhibit B cell activity without depleting them, with a BLA under FDA review for IgG4-Related Disease and Phase 2 trials in systemic lupus erythematosus; and orelabrutinib, a highly selective CNS-penetrant oral BTK inhibitor advancing in Phase 3 trials for primary progressive and non-active secondary progressive multiple sclerosis. Earlier-stage programs include ZB021, an oral IL-17AA/AF inhibitor in Phase 1 partnership with InnoCare Pharma targeting dermatologic and rheumatic diseases; ZB022, a preclinical oral brain-penetrant TYK2 inhibitor; and ZB014, a half-life extended anti-CD19/FcγRIIb antibody designed for once-monthly dosing. The company acquires and in-licenses product candidates globally, partnering with organizations including Bristol Myers Squibb (obexelimab in Asia-Pacific), InnoCare Pharma (orelabrutinib and ZB021), and Xencor. Manufacturing of obexelimab is conducted through WuXi Biologics in China. Updated Aug 13, 2026